ArticleThe oncologist2025
How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes.
Zena Chahine et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it